40.23 +0.01 (0.02%)
After hours: 5:25PM EDT
|Bid||40.21 x 2200|
|Ask||40.22 x 1800|
|Day's Range||39.89 - 40.24|
|52 Week Range||36.41 - 42.36|
|Beta (3Y Monthly)||0.54|
|PE Ratio (TTM)||40.54|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||2.39 (5.71%)|
|1y Target Est||44.33|
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive first-quarter sales. However, genericization of key drugs and increasing competition are concerns.
Pfizer (NYSE:PFE) stock has missed out on the exuberant bull market this year, as the indexes have hit all-time highs, but Pfizer stock has fallen about 10% in 2019.Source: Shutterstock Then again, the company's growth has been lagging, and PFE has felt pressure from Washington, DC to reduce its drug prices.But next week we'll get more information on the status of the company, as it will report its first-quarter results. They will be announced on Apr. 30 before the market opens.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Dividend Stocks That Could Double Over the Next Five Years Analysts' expectations for Pfizer stock are fairly muted. For the quarter, on average they predict that its revenues will be $13 billion and its earnings will be 75 cents per share of Pfizer stock By comparison, in the same period a year ago, its revenues were $12.9 billion and its earnings were 77 cents per share.It's important to keep in mind that, when PFE last reported its financial results, it provided full-year revenue guidance of $52 billion to $54 billion. Last year, its top line came in at $53.6 billion.The big issue for Pfizer stock has been its pain killer, Lyrica. This drug, which generated close to $5 billion of revenue last year, will lose its patent protection in June. Moreover, the sales of a number of PFE's other drugs have slowed this year.But PFE's pipeline does look promising, creating potential positive catalysts for PFE stock. Last quarter, the company announced several positive catalysts involving its pipeline. Specifically: * Pfizer and Bristol-Myers Squibb (NYSE:BMY) have been developing a new version of Eliquis, which has been shown to effectively treat the bleeding of heart attack patients. A recent study of Eliquis indicated that its efficacy in this area was significantly better than that of a warfarin combination. * The FDA granted a Breakthrough Therapy Designation for Pfizer's 20-Valent Pneumococcal Conjugate Vaccine (20vPnC). The treatment is supposed to prevent people from getting pneumonia, and it appears to be much more effective than the vaccines that are currently on the market. * The European Commission approved VIZIMPRO, which is a treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC). * In Q1, Pfizer continued its big push into the gene-therapy market. The company announced that it had created a partnership with Vivet Therapeutics. The companies will focus on developing a treatment for Wilson disease , a rare condition that leads to copper poisoning. * The FDA approved Pfizer's TRAZIMERA, a treatment for breast cancer.Going forward, a number of Pfizer's major drugs, including Xeljanz and Ibrance., should be approved as treatments for additional diseases. Furthermore, the sales of several other Pfizer treatments -including atopic dermatitis treatments tafamidis and abrocitinib, as well as pain medication tanezumab - could surge tremendously. The Bottom Line on Pfizer StockPfizer stock is trading at reasonable levels, as its forward price-earnings ratio is below 13. That's in-line with the valuations of other mega pharma operators like Merck (NYSE:MRK) and GlaxoSmithKline (NYSE:GSK).Pfizer also has a long history of being shareholder-friendly. The dividend yield of PFE stock is 3.4% and the company continues to buyback large amounts of Pfizer stock. PFE bought back $12.2 billion of PFE stock last year.However, there probably will not be any near-term catalysts for PFE stock. The political pressure will remain an overhang on Pfizer stock, especially as we get closer to the presidential election. Meanwhile, it will take some time for the company's pipeline to boost its revenue and profits. As a result, investors shouldn't rush to buy Pfizer stock.Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks That Could Double Over the Next Five Years * 6 S&P 500 Stocks Ready to Break Out * 5 Mining ETFs to Dig Into Compare Brokers The post Pfizer Stock Has Positive and Negative Catalysts Going Into Results appeared first on InvestorPlace.
Exelixis' (EXEL) first-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.
The FTSE 100 is an index that includes the top 100 companies from the London Stock Exchange. They are ranked by their market capitalization. However, market cap may not be an investor’s only interest in a stock.
HAMILTON, Mont. (AP) — Drugmaker GlaxoSmithKline has announced $100 million of new investment in its manufacturing site in Montana.
A large-scale pilot of a vaccine that could prevent some of the 250,000 child deaths each year from malaria has begun in Malawi after successful clinical trials. The vaccine — called RTS,S — acts against the most deadly malaria parasite and has been in development by GlaxoSmithKline for more than three decades. According to the World Health Organization, it is the first vaccine to demonstrate it can significantly reduce cases of malaria in children.
Alexion's (ALXN) first-quarter 2019 results are likely to gain on solid performance of lead drug, Soliris. Investors will also focus on updates on pipeline candidates.
Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
The changes are part of a new approach to R&D; prioritizing innovation and moving towards delivering a pipeline of medicines with a focus on immunology.
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
A recent FDA approval has one Triangle pharmaceutical company going head to head with the likes Pharma giants such as GSK – in an multi-billion dollar industry company officials believe they have the edge in.
Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.
Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
(Reuters) - Britain's main index lost ground on Monday as miners and oil majors fell, more than offsetting gains in bank stocks. The FTSE 100 was 0.2 percent lower, lagging its European and Asian counterparts, ...
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.